专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060252716A1 Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" 审中-公开
标题翻译：逆转黑色素瘤抑制活性的免疫抑制作用的方法“mia”
公开(公告)号：US20060252716A1
公开(公告)日：2006-11-09
申请号：US10220265
申请日：2001-03-10
申请人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Rainer Apfel , Wolfgang Brysch , Piotr Jachimczak , Ulrich Bogdahn
发明人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Rainer Apfel , Wolfgang Brysch , Piotr Jachimczak , Ulrich Bogdahn
IPC分类号： A61K48/00
CPC分类号： A61K38/1709 , A61K31/70 , A61K31/7088 , A61K39/395
摘要： A method for stimulating immune cells and/or the immune system, and/or reducing invasion and/or metastasis of tumor cells by inhibiting expression and/or functional activity of “Melanoma Inhibitory Activity” MIA.
摘要翻译：通过抑制“黑素瘤抑制活性”MIA的表达和/或功能活性来刺激免疫细胞和/或免疫系统和/或减少肿瘤细胞的侵袭和/或转移的方法。

2. 发明授权

US07667027B2 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β) 失效
标题翻译：用于治疗转化生长因子的免疫抑制作用的反义寡核苷酸（TGF-＆bgr）
公开(公告)号：US07667027B2
公开(公告)日：2010-02-23
申请号：US11647586
申请日：2006-12-29
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： C07H21/04
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译：与编码转化生长因子的基因的区域杂交的反义寡核苷酸或其有效的衍生物; （TGF-β），其包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。

3. 发明申请

US20080214483A1 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta) 失效
标题翻译：用于治疗转化生长因子-β（TGF-β）的免疫抑制作用的反义寡核苷酸
公开(公告)号：US20080214483A1
公开(公告)日：2008-09-04
申请号：US11647586
申请日：2006-12-29
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： A61K31/711 , C07H21/04
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-β (TGF-β) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译：与编码转化生长因子-β（TGF-β）的基因的区域杂交的反义寡核苷酸或其有效衍生物包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。

4. 发明授权

US06455689B1 Antisense-oligonucleotides for transforming growth factor-&bgr; (TGF-&bgr;) 失效
标题翻译：用于转化生长因子-β（TGF-β）的反义寡核苷酸
公开(公告)号：US06455689B1
公开(公告)日：2002-09-24
申请号：US08535249
申请日：1995-10-30
申请人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
发明人： Georg-Ferdinand Schlingensiepen , Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Ulrich Bogdahn
IPC分类号： C07H2102
CPC分类号： C12N15/1136 , C12N2310/315
摘要： Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&bgr; (TGF-&bgr;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.
摘要翻译：与编码转化生长因子-β（TGF-β）的基因的区域杂交的反义寡核苷酸或其有效衍生物包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 1-56和137，或包含在SEQ ID NO：1的序列表中鉴定的以下核酸序列。 57〜136个具有DNA或RNA型结构的核酸。

5. 发明授权

US06365345B1 Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role 失效
标题翻译：用于预防和治疗其中c-erbB表达起作用的病症的反义核酸
公开(公告)号：US06365345B1
公开(公告)日：2002-04-02
申请号：US08666341
申请日：1996-08-15
申请人： Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Georg-Ferdinand Schlingensiepen
发明人： Wolfgang Brysch , Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Georg-Ferdinand Schlingensiepen
IPC分类号： C07H2104
CPC分类号： A61K31/70 , C12N15/1138
摘要： The present invention is related to an antisense-nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the p185erbB-2 receptor (also termed c-erbB-2, HER2 or neu), a pharmaceutical composition, comprising an antisense nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the c-erbB-2 receptor as well as the use of said antisense nucleic acids and derivatives thereof for the manufacturing of a pharmaceutical composition for the treatment of neoplasms and/or immune diseases and/or diseases involving pathological angiogenesis.
摘要翻译：本发明涉及与编码p185erbB-2受体（也称为c-erbB-2，HER2或neu）的信使RNA（mRNA）或DNA的区域杂交的反义核酸或其有效衍生物，一种药物组合物，其包含与编码c-erbB-2受体的信使RNA（mRNA）或DNA的区域杂交的反义核酸或其有效衍生物，以及将所述反义核酸及其衍生物用于用于治疗涉及病理性血管发生的肿瘤和/或免疫疾病和/或疾病的药物组合物的制造。

6. 发明申请

US20080124301A1 Method for stimulating the immune system 失效
标题翻译：刺激免疫系统的方法
公开(公告)号：US20080124301A1
公开(公告)日：2008-05-29
申请号：US11898080
申请日：2007-09-07
申请人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Wolfgang Brysch
发明人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Wolfgang Brysch
IPC分类号： A61K38/20 , A61K31/7052 , A61K35/76 , A61K39/12 , A61K39/00 , A61K35/12 , C07H21/00 , A61P37/04
CPC分类号： A61K45/06 , A61K2039/505
摘要： Medicament comprising a combination of at least one inhibitor of the effect of a substance negatively effecting an immune response, the substance selected from the group consisting of TGF-β and its receptors, VEGF and its receptors, interleukin 10 (IL-10) and its receptors, PGE2 and its receptors, wherein the inhibitor has a molecular weight of less than 100 kDa and at least one stimulator positively effecting an immune response.
摘要翻译：药物，其包含至少一种负面影响免疫应答的物质的作用抑制剂的组合，所述物质选自TGF-β及其受体，VEGF及其受体，白介素10（IL-10）及其受体受体，PGE 2和其受体，其中抑制剂具有小于100kDa的分子量和至少一种积极影响免疫应答的刺激物。

7. 发明授权

US08629117B2 Method for stimulating the immune system 失效
标题翻译：刺激免疫系统的方法
公开(公告)号：US08629117B2
公开(公告)日：2014-01-14
申请号：US11898080
申请日：2007-09-07
申请人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Wolfgang Brysch
发明人： Karl-Hermann Schlingensiepen , Reimar Schlingensiepen , Wolfgang Brysch
IPC分类号： A01N43/04 , C12Q1/68 , C12P19/34 , C07H21/02 , C07H21/04
CPC分类号： A61K45/06 , A61K2039/505
摘要： Medicament comprising a combination of at least one inhibitor of the effect of a substance negatively effecting an immune response, the substance selected from the group consisting of TGF-β and its receptors, VEGF and its receptors, interleukin 10 (IL-10) and its receptors, PGE2 and its receptors, wherein the inhibitor has a molecular weight of less than 100 kDa and at least one stimulator positively effecting an immune response.
摘要翻译：药物，其包含至少一种负面影响免疫应答的物质的作用抑制剂的组合，所述物质选自TGF-β及其受体，VEGF及其受体，白介素10（IL-10）及其受体受体，PGE2及其受体，其中所述抑制剂具有小于100kDa的分子量和至少一种正向影响免疫应答的刺激物。

8. 发明授权

US07326783B2 Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms 失效
标题翻译：包含用于预防和/或治疗神经元损伤，变性和细胞死亡以及用于治疗赘生物的反义核酸的药物组合物
公开(公告)号：US07326783B2
公开(公告)日：2008-02-05
申请号：US08591486
申请日：1994-07-06
申请人： Georg-F Schlingensiepen , Reimar Schlingensiepen , Karl-Hermann Schlingensiepen , Wolfgang Brysch
发明人： Georg-F Schlingensiepen , Reimar Schlingensiepen , Karl-Hermann Schlingensiepen , Wolfgang Brysch
IPC分类号： C07H21/04 , C07H21/00
CPC分类号： C12N15/1135 , C12N2310/315
摘要： A pharmaceutical composition comprising an effective amount of a compound which is capable from preventing and treating neuronal injury, degeneration, cell death and/or neoplasms in which expression of c-jun, c-fos or jun-B plays a causal role which compound being an antisense nucleic acid or effective derivative thereof, said antisense nucleic acid hybridizing with an area of the messenger RNA (mRNA) and/or DNA encoding c-jun, c-fos or jun-B.
摘要翻译：一种药物组合物，其包含有效量的能够预防和治疗其中c-jun，c-fos或jun-B的表达具有因果作用的神经元损伤，变性，细胞死亡和/或赘生物的化合物，该化合物为反义核酸或其有效衍生物，所述反义核酸与编码c-jun，c-fos或jun-B的信使RNA（mRNA）和/或DNA的区域杂交。

9. 发明申请

US20050130927A1 Antisense oligonucleotide preparation method 失效
标题翻译：反义寡核苷酸制备方法
公开(公告)号：US20050130927A1
公开(公告)日：2005-06-16
申请号：US10984919
申请日：2004-11-10
申请人： Karl-Hermann Schlingensiepen , Wolfgang Brysch
发明人： Karl-Hermann Schlingensiepen , Wolfgang Brysch
IPC分类号： C12N15/09 , A61K31/70 , A61K31/7088 , A61K31/7125 , A61K38/00 , A61K48/00 , A61P3/00 , A61P9/10 , A61P25/28 , A61P31/00 , A61P35/00 , A61P37/00 , C07H21/02 , C07H21/04 , C12N15/113 , C12P19/34 , C12Q1/68
CPC分类号： C12N15/1136 , A61K38/00 , C07H21/02 , C07H21/04 , C12N15/113 , C12N15/1135 , C12N15/1138 , C12N2310/11 , C12N2310/3125 , C12N2310/3145 , C12N2310/315 , C12N2310/3181 , C12N2310/351
摘要： A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications: 3H-bond-R/3H-bond-R+2H-bond-R≧0.29; and synthesizing the oligonucleotide thus generated in a per se known manner.
摘要翻译：一种制备反义寡核苷酸或其衍生物的方法，包括以下步骤：如果需要，选择靶核酸阐明其序列; 产生反义寡核苷酸，条件是：寡核苷酸包含至少8个残基; 该寡核苷酸包含最多12个元件，其能够形成各自与胞嘧啶碱基的三个氢键; 寡核苷酸不含有四个或更多个连续的元件，能够在目标分子内形成三个氢键，每个具有四个连续的胞嘧啶碱基（CCCC），或者四个或更多个连续的GGGG元件; 寡核苷酸还不含有两个或更多个三个连续元件的系列，能够在目标分子内形成三个连接的胞嘧啶碱基（CCC）的三个氢键，或者另外两个或更多个三个连续的GGG元件系列; 并且与目标分子形成每个残基（2H-键-R）的两个氢键与每个残基形成三个氢键（3H-键-R）的残基与靶分子之间的比例由下列规格表示： 3H键-R / 3H键-R + 2H-键-R = 0.29; 并以本身已知的方式合成由此产生的寡核苷酸。

10. 发明授权

US07563778B2 Antisense oligonucleotide preparation method 失效
标题翻译：反义寡核苷酸制备方法
公开(公告)号：US07563778B2
公开(公告)日：2009-07-21
申请号：US10984919
申请日：2004-11-10
申请人： Karl-Hermann Schlingensiepen , Wolfgang Brysch
发明人： Karl-Hermann Schlingensiepen , Wolfgang Brysch
IPC分类号： A01N43/04 , C11Q1/68 , C12P19/34 , C07H21/02 , C07H21/04
CPC分类号： C12N15/1136 , A61K38/00 , C07H21/02 , C07H21/04 , C12N15/113 , C12N15/1135 , C12N15/1138 , C12N2310/11 , C12N2310/3125 , C12N2310/3145 , C12N2310/315 , C12N2310/3181 , C12N2310/351
摘要： A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications: 3H-bond-R/3H-bond-R+2H-bond-R≧0.29; and synthesizing the oligonucleotide thus generated in a per se known manner.
摘要翻译：一种制备反义寡核苷酸或其衍生物的方法，包括以下步骤：如果需要，选择靶核酸阐明其序列; 产生反义寡核苷酸，条件是：寡核苷酸包含至少8个残基; 该寡核苷酸包含最多12个元件，其能够形成各自与胞嘧啶碱基的三个氢键; 寡核苷酸不含有四个或更多个连续的元件，能够在目标分子内形成三个氢键，每个具有四个连续的胞嘧啶碱基（CCCC），或者四个或更多个连续的GGGG元件; 寡核苷酸还不含有两个或更多个三个连续元件的系列，能够在目标分子内形成三个连接的胞嘧啶碱基（CCC）的三个氢键，或者另外两个或更多个三个连续的GGG元件系列; 并且与目标分子形成每个残基（2H-键-R）的两个氢键与每个残基形成三个氢键（3H-键-R）的残基与靶分子之间的比例由下列规格表示： 3H键-R / 3H键-R + 2H-键-R = 0.29; 并以本身已知的方式合成由此产生的寡核苷酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式